SCHEMBL6447694

SCHEMBL6447694

CC1CN(c2ccncc2)Cc2ccccc21

nearest known ligand 1.00 ✓ in ChEMBL — recovers established targets

Predicted protein targets (top 16)

geneUniProtsupporting neighboursconfidence
EED O75530 1/20 0.51
SLC6A2 P23975 3/20 0.40
SLC6A4 P31645 3/20 0.40
SLC6A3 Q01959 3/20 0.40
ABHD6 Q9BV23 1/20 0.39
HTR2A P28223 1/20 0.38
HTR2C P28335 1/20 0.38
HTR2B P41595 1/20 0.38
CHKA P35790 1/20 0.38
LMNA P02545 1/20 0.36
KDM4E B2RXH2 1/20 0.36
NPC1 O15118 1/20 0.36
RAB9A P51151 1/20 0.36
RECQL P46063 1/20 0.36
DDR1 Q08345 1/20 0.35
DDR2 Q16832 1/20 0.35

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL23112130 0.80 DDR1 (0.37) SLC6A2SLC6A4SLC6A3ABHD6HTR2A
SCHEMBL6591115 0.75 EED (0.75) EEDCHKAKDM4ENPC1RAB9A
SCHEMBL29728369 0.74 DDR1 (0.49) DDR1DDR2
SCHEMBL6591541 0.74 TIPARP (0.43) EEDSLC6A2SLC6A4SLC6A3LMNA
SCHEMBL6440014 0.72 GRIN2D (0.58)
SCHEMBL23112157 0.72 ROCK1 (0.43) SLC6A2SLC6A4SLC6A3ABHD6HTR2A
SCHEMBL19046849 0.71 ABHD6 (0.51) SLC6A2SLC6A4SLC6A3ABHD6HTR2A
SCHEMBL22183794 0.71 ABHD6 (0.51) SLC6A2SLC6A4SLC6A3ABHD6HTR2A
SCHEMBL19021474 0.71 SLC6A2 (0.66) SLC6A2SLC6A4SLC6A3HTR2AHTR2C
SCHEMBL11937063 0.71 SLC6A2 (0.66) SLC6A2SLC6A4SLC6A3HTR2AHTR2C

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 5 patents. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
EP-1448547-B1 PYRIDINE DERIVATIVES AS NMDA RECEPTOR LIGANDS HOFFMANN LA ROCHE (CH) 2005-04-20 EP disclosed
US-6831087-B2 2-(Pyrid-2- or 4-yl)-1,2,3,4-tetrahydroisoquinoline and derivatives; a good affinity to the NMDA receptor (N-methyl-D-asparate); acute/cronic neurodegenerative diseases; bacterial/viral infections; antidepressants; analgesics HOFFMANN-LA ROCHE INC. 2004-12-14 US disclosed
EP-1448547-A1 PYRIDINE DERIVATIVES AS NMDA RECEPTOR LIGANDS F. HOFFMANN-LA ROCHE AG (CH) 2004-08-25 EP disclosed
US-20030119870-A1 Pyridine substituted isoquinoline derivatives F. HOFFMANN-LA ROCHE AG (CH) 2003-06-26 US disclosed
WO-2003040128-A1 PYRIDINE DERIVATIVES AS NMDA RECEPTOR LIGANDS F. HOFFMANN-LA ROCHE AG (CH) 2003-05-15 WO disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20030119870-A1 Pyridine substituted isoquinoline derivatives GRIN1, GRIN2C, GRIN2A EED 2041/4885SLC6A2 364/4885SLC6A4 304/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.